Close X
Attorney Spotlight

Learn about Doug Dahl's practice and find out about an interesting trend happening in the employee benefits field. Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

FCPA: 2016 Year in Review & 2017 Enforcement Predictions

A review of trends and developments in FCPA as well as a look ahead into what to expect for 2017. This report aims at providing corporate leaders and companies with the knowledge they need to comply with the FCPA and avoid litigation in 2017.

Read now

Danielle Sloane and Courtney Ginn Discuss FDA Enforcement Related to Labs Marketing Directly to Consumers

G2 Compliance Advisor

Publications

March 23, 2016

Bass, Berry & Sims attorneys Danielle Sloane and Courtney Ginn authored an article outlining the new FDA enforcement actions against laboratory developed tests (LDTs) that are marketed and sold directly to consumers. Although LDTs have historically been exempt from FDA regulation, as technology and testing options have developed and become more sophisticated, more regulation may be on the horizon for these types of tests. As Danielle and Courtney point out in the article, "[i]In late 2015 and early 2016, the FDA issued five warning letters to companies engaging in DTC [direct to consumers] marketing of LDTs. In several of these letters, it appears the FDA may be going beyond situations in which the consumer can order the test directly to also regulate situations in which the practitioner signing the order is affiliated with the laboratory."

The full article, "Marketing of Laboratory Tests to Consumers: Is a Practitioner Order Enough to Avoid FDA Enforcement," was published in the March 2016 issue of G2 Compliance Advisor and is available online (subscription required).


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.